Skip to main content
SpringerLink
Log in

Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy

  • 2018 SSAT Plenary Presentation
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Introduction

Approximately, 20% of patients with pancreatic ductal adenocarcinoma have resectable disease at diagnosis. Given improvements in locoregional and systemic therapies, some patients with borderline resectable pancreatic cancer (BRPC) can now undergo successful resection. The outcomes of patients with BRPC after neoadjuvant therapy remain unclear.

Methods

A prospectively maintained single-institution database was utilized to identify patients with BRPC who were managed at the Johns Hopkins Pancreas Multidisciplinary Clinic (PMDC) between 2013 and 2016. BRPC was defined as any tumor that presented with radiographic evidence of the involvement of the portal vein (PV) or superior mesenteric vein (SMV) that was deemed to be technically resectable (with or without the need for reconstruction), or the abutment (< 180° involvement) of the common hepatic artery (CHA) or superior mesenteric artery (SMA), in the absence of involvement of the celiac axis (CA). We collected data on treatment, the course of the disease, resection rate, and survival.

Results

Of the 866 patients evaluated at the PMDC during the study period, 151 (17.5%) were staged as BRPC. Ninety-six patients (63.6%) underwent resection. Neoadjuvant chemotherapy was administered to 142 patients (94.0%), while 78 patients (51.7%) received radiation therapy in the neoadjuvant setting. The median overall survival from the date of diagnosis, of resected BRPC patients, was 28.8 months compared to 14.5 months in those who did not (p < 0.001). Factors associated with increased chance of surgical resection included lower ECOG performance status (p = 0.011) and neck location of the tumor (p = 0.001). Forty-seven patients with BRPC (31.1%) demonstrated progression of disease; surgical resection was attempted and aborted in 12 patients (7.9%). Eight patients (5.3%) were unable to tolerate chemotherapy; six had disease progression and two did not want to pursue surgery. Lastly, four patients (3.3%) were conditionally unresectable due to medical comorbidities at the time of diagnosis due to comorbidities and failed to improve their status and subsequently had progression of the disease.

Conclusion

After initial management, 31.1% of patients with BRPC have progression of disease, while 63.6% of all patients successfully undergo resection, which was associated with improved survival. Factors associated with increased likelihood of surgical resection include lower ECOG performance status and tumor location in the neck.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a Cancer Journal for Clinicians. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442.

    Article  Google Scholar 

  2. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK et al. Recent progress in pancreatic cancer. CA: a Cancer Journal for Clinicians. 2013;63(5):318–48. https://doi.org/10.3322/caac.21190.

    Article  Google Scholar 

  3. Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA et al. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgery. 2018. https://doi.org/10.1097/SLA.0000000000002734.

  4. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN. 2017;15(8):1028–61. https://doi.org/10.6004/jnccn.2017.0131.

    Article  PubMed  Google Scholar 

  5. Javed AA, Bleich K, Bagante F, He J, Weiss MJ, Wolfgang CL et al. Pancreaticoduodenectomy with venous resection and reconstruction: current surgical techniques and associated postoperative imaging findings. Abdominal Radiology (New York). 2017. https://doi.org/10.1007/s00261-017-1290-5.

  6. Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World Journal of Gastroenterology. 2014;20(31):10740–51. https://doi.org/10.3748/wjg.v20.i31.10740.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cooper AB, Tzeng CW, Katz MH. Treatment of borderline resectable pancreatic cancer. Current Treatment Options in Oncology. 2013;14(3):293–310. https://doi.org/10.1007/s11864-013-0244-6.

    Article  PubMed  Google Scholar 

  8. McClaine RJ, Lowy AM, Sussman JJ, Schmulewitz N, Grisell DL, Ahmad SA. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB: the Official Journal of the International Hepato Pancreato Biliary Association. 2010;12(1):73–9. https://doi.org/10.1111/j.1477-2574.2009.00136.x.

    Article  Google Scholar 

  9. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Annals of Surgical Oncology. 2015;22(4):1153–9. https://doi.org/10.1245/s10434-014-4225-1.

    Article  PubMed  Google Scholar 

  10. Abrams RA, Lowy AM, O’Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Annals of Surgical Oncology. 2009;16(7):1751–6. https://doi.org/10.1245/s10434-009-0413-9.

    Article  PubMed  Google Scholar 

  11. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Annals of Surgery. 1995;221(1):59–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Russo S, Ammori J, Eads J, Dorth J. The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncology. 2016;12(5):669–85. https://doi.org/10.2217/fon.15.335.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. Journal of the American College of Surgeons. 2008;206(5):833–46; discussion 46–8. https://doi.org/10.1016/j.jamcollsurg.2007.12.020.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Isaji S, Mizuno S, Windsor JA, Bassi C, Fernandez-Del Castillo C, Hackert T et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology: official journal of the International Association of Pancreatology. 2018;18(1):2–11. https://doi.org/10.1016/j.pan.2017.11.011.

    Article  Google Scholar 

  15. Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH et al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Annals of Surgery. 2018. https://doi.org/10.1097/SLA.0000000000002705.

  16. Epstein JD, Kozak G, Fong ZV, He J, Javed AA, Joneja U et al. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. Journal of Surgical Oncology. 2017;116(6):658–64. https://doi.org/10.1002/jso.24723.

    Article  PubMed  Google Scholar 

  17. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008;26(21):3496–502. https://doi.org/10.1200/JCO.2007.15.8634.

    Article  CAS  Google Scholar 

  18. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Medicine. 2010;7(4):e1000267. https://doi.org/10.1371/journal.pmed.1000267.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Blair AB, Rosati LM, Rezaee N, Gemenetzis G, Zheng L, Hruban RH et al. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Surgery. 2018;163(5):1090–6. https://doi.org/10.1016/j.surg.2017.11.027.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers. 2018;10(1). https://doi.org/10.3390/cancers10010024.

  21. Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O’Reilly EM et al. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World Journal of Surgical Oncology. 2017;15(1):183. https://doi.org/10.1186/s12957-017-1240-2.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E et al. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surgery. 2016;151(8):e161137. https://doi.org/10.1001/jamasurg.2016.1137.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Quan K, Sutera P, Xu K, Bernard ME, Burton SA, Wegner RE et al. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma. Practical Radiation Oncology. 2018;8(2):95–106. https://doi.org/10.1016/j.prro.2017.10.001.

    Article  PubMed  Google Scholar 

  24. Kim HS, Jang JY, Han Y, Lee KB, Joo I, Lee DH et al. Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer. Annals of Surgical Treatment and Research. 2017;93(4):186–94. https://doi.org/10.4174/astr.2017.93.4.186.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK et al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Annals of Surgery. 2018. https://doi.org/10.1097/SLA.0000000000002753.

  26. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199. https://doi.org/10.1186/1471-2407-12-199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Joo I, Lee JM, Lee ES, Ahn SJ, Lee DH, Kim SW et al. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. AJR: American Journal of Roentgenology. 2018;210(5):1059–65. https://doi.org/10.2214/AJR.17.18310.

    Article  PubMed  Google Scholar 

  28. Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Annals of Surgery. 2015;261(1):12–7. https://doi.org/10.1097/SLA.0000000000000867.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Shrestha B, Sun Y, Faisal F, Kim V, Soares K, Blair A et al. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Medicine. 2017;6(7):1552–62. https://doi.org/10.1002/cam4.1104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R et al. Alliance for Clinical Trials in Oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017;17(1):505. https://doi.org/10.1186/s12885-017-3441-z.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Halsted 614, Baltimore, MD, 21287, USA

    Ammar A. Javed, Michael J. Wright, Ayat Siddique, Alex B. Blair, Richard A. Burkhart, Martin Makary, John L. Cameron, Matthew J. Weiss, Christopher Wolfgang & Jin He

  2. The Pancreatic Cancer Precision Medicine Center of Excellence Program, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Ammar A. Javed, Michael J. Wright, Ayat Siddique, Alex B. Blair, Ding Ding, Richard A. Burkhart, Martin Makary, John L. Cameron, Amol Narang, Joseph Herman, Lei Zheng, Daniel Laheru, Matthew J. Weiss, Christopher Wolfgang & Jin He

  3. Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Ding Ding, Lei Zheng & Daniel Laheru

  4. Department of Radiation Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Amol Narang & Joseph Herman

Authors
  1. Ammar A. Javed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ayat Siddique
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alex B. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ding Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard A. Burkhart
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Martin Makary
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John L. Cameron
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Amol Narang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Joseph Herman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lei Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Daniel Laheru
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Matthew J. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Christopher Wolfgang
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jin He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin He.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Javed, A.A., Wright, M.J., Siddique, A. et al. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. J Gastrointest Surg 23, 112–121 (2019). https://doi.org/10.1007/s11605-018-3966-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-018-3966-8

Keywords

Search

Navigation